These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 24712857)

  • 81. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer.
    Yu J; Du W; Yan F; Wang Y; Li H; Cao S; Yu W; Shen C; Liu J; Ren X
    J Immunol; 2013 Apr; 190(7):3783-97. PubMed ID: 23440412
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Design, synthesis and biological evaluation of thioether-containing lenalidomide and pomalidomide derivatives with anti-multiple myeloma activity.
    Wang Y; Mi T; Li Y; Kan W; Xu G; Li J; Zhou Y; Li J; Jiang X
    Eur J Med Chem; 2021 Jan; 209():112912. PubMed ID: 33328101
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Immunomodulatory Drugs (IMiDs) in Multiple Myeloma.
    Raza S; Safyan RA; Lentzsch S
    Curr Cancer Drug Targets; 2017; 17(9):846-857. PubMed ID: 28201976
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications.
    Bjorklund CC; Baladandayuthapani V; Lin HY; Jones RJ; Kuiatse I; Wang H; Yang J; Shah JJ; Thomas SK; Wang M; Weber DM; Orlowski RZ
    Leukemia; 2014 Feb; 28(2):373-83. PubMed ID: 23760401
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Disseminated keratotic spicules: a rare manifestation in multiple myeloma and successful response to lenalidomide.
    Vivas AC; Chimento SM; Herschthal J; Spock C; Alonso-Llamazares J
    J Am Acad Dermatol; 2013 Jun; 68(6):e179-80. PubMed ID: 23680209
    [No Abstract]   [Full Text] [Related]  

  • 86. Immunomodulatory drugs in multiple myeloma.
    Zangari M; Elice F; Tricot G
    Expert Opin Investig Drugs; 2005 Nov; 14(11):1411-8. PubMed ID: 16255679
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Interleukin‑33‑induced immune tolerance is associated with the imbalance of memory and naïve T‑lymphocyte subsets.
    Shi X; Tang Y; Sun X; Liu Y; Sun Y; Sun M; Jiang Y; Li Y
    Mol Med Rep; 2016 Nov; 14(5):4837-4843. PubMed ID: 27748878
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab.
    van der Veer MS; de Weers M; van Kessel B; Bakker JM; Wittebol S; Parren PW; Lokhorst HM; Mutis T
    Haematologica; 2011 Feb; 96(2):284-90. PubMed ID: 21109694
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Pomalidomide: new immunomodulatory agent with potent antiproliferative effects.
    Richardson PG; Mark TM; Lacy MQ
    Crit Rev Oncol Hematol; 2013 Oct; 88 Suppl 1():S36-44. PubMed ID: 23786844
    [TBL] [Abstract][Full Text] [Related]  

  • 90. The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy.
    Hsu AK; Quach H; Tai T; Prince HM; Harrison SJ; Trapani JA; Smyth MJ; Neeson P; Ritchie DS
    Blood; 2011 Feb; 117(5):1605-13. PubMed ID: 20978269
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Comparative effectiveness and safety of thalidomide and lenalidomide in patients with multiple myeloma in the United States of America: A population-based cohort study.
    Luo J; Gagne JJ; Landon J; Avorn J; Kesselheim AS
    Eur J Cancer; 2017 Jan; 70():22-33. PubMed ID: 27866096
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Potential new risks of lenalidomide.
    Gertz MA; Buadi FK
    Leuk Lymphoma; 2014 Sep; 55(9):1962-3. PubMed ID: 24304420
    [No Abstract]   [Full Text] [Related]  

  • 93. Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell-mediated cytotoxicity.
    Hagner PR; Chiu H; Ortiz M; Apollonio B; Wang M; Couto S; Waldman MF; Flynt E; Ramsay AG; Trotter M; Gandhi AK; Chopra R; Thakurta A
    Br J Haematol; 2017 Nov; 179(3):399-409. PubMed ID: 28771673
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Bone marrow myeloid cells in regulation of multiple myeloma progression.
    Herlihy SE; Lin C; Nefedova Y
    Cancer Immunol Immunother; 2017 Aug; 66(8):1007-1014. PubMed ID: 28378067
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Changes in immune cell populations following KappaMab, lenalidomide and low-dose dexamethasone treatment in multiple myeloma.
    Norton SE; Khong T; Ramachandran M; Highton AJ; Ward-Hartstonge KA; Shortt J; Spencer A; Kemp RA
    Clin Transl Immunology; 2023; 12(12):e1478. PubMed ID: 38034081
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma.
    Sklavenitis-Pistofidis R; Aranha MP; Redd RA; Baginska J; Haradhvala NJ; Hallisey M; Dutta AK; Savell A; Varmeh S; Heilpern-Mallory D; Ujwary S; Zavidij O; Aguet F; Su NK; Lightbody ED; Bustoros M; Tahri S; Mouhieddine TH; Wu T; Flechon L; Anand S; Rosenblatt JM; Zonder J; Vredenburgh JJ; Boruchov A; Bhutani M; Usmani SZ; Matous J; Yee AJ; Jakubowiak A; Laubach J; Manier S; Nadeem O; Richardson P; Badros AZ; Mateos MV; Trippa L; Getz G; Ghobrial IM
    Cancer Cell; 2022 Nov; 40(11):1358-1373.e8. PubMed ID: 36379208
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Tasquinimod suppresses tumor cell growth and bone resorption by targeting immunosuppressive myeloid cells and inhibiting c-MYC expression in multiple myeloma.
    Fan R; Satilmis H; Vandewalle N; Verheye E; Vlummens P; Maes A; Muylaert C; De Bruyne E; Menu E; Evans H; Chantry A; De Beule N; Hose D; Törngren M; Eriksson H; Vanderkerken K; Maes K; Breckpot K; De Veirman K
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36650020
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Lenalidomide triggers T-cell effector functions in vivo in patients with follicular lymphoma.
    Ménard C; Rossille D; Dulong J; Nguyen TT; Papa I; Latour M; Bescher N; Bezier I; Chouteau M; Fest T; Houot R; Morschhauser F; Tarte K
    Blood Adv; 2021 Apr; 5(8):2063-2074. PubMed ID: 33877296
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Deep Immune Profiling of Multiple Myeloma at Diagnosis and under Lenalidomide Maintenance Therapy.
    Luoma S; Sergeev P; Javarappa KK; Öhman TJ; Varjosalo M; Säily M; Anttila P; Sankelo M; Partanen A; Nihtinen A; Heckman CA; Silvennoinen R
    Cancers (Basel); 2023 May; 15(9):. PubMed ID: 37174069
    [TBL] [Abstract][Full Text] [Related]  

  • 100. The Immunomodulatory Effects of Honey and Associated Flavonoids in Cancer.
    Masad RJ; Haneefa SM; Mohamed YA; Al-Sbiei A; Bashir G; Fernandez-Cabezudo MJ; Al-Ramadi BK
    Nutrients; 2021 Apr; 13(4):. PubMed ID: 33924384
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.